Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 6Thiotepa 5Granulocyte Colony-Stimulating Factor 4Filgrastim 4Etoposide 4Cisplatin 4Busulfan 4tislelizumab 3Melphalan 3Carboplatin 3tazemetostat 2regorafenib 2pembrolizumab 2belinostat 2Topotecan 2Temozolomide 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Mesna 2Ifosfamide 2Doxorubicin 2spartalizumab 1sodium thiosulfate 1sargramostim 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1entinostat 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × LY2940680 × Other solid neoplasm × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡